30069-31-9

Basic information

• Product Name: N-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide
• Synonyms: N-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide
• CAS NO: 30069-31-9
• Molecular Formula: C₁₅H₁₃F₃N₂O
• Molecular Weight: 294.2717296
• Mol File: 30069-31-9.mol
• Article Data: 27

Chemical Properties

• Boiling Point: 338.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.335±0.06 g/cm3(Predicted)
• PKA: 12.88±0.70(Predicted)
• CAS DataBase Reference: N-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide(30069-31-9)
• EPA Substance Registry System: N-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide(30069-31-9)

Safety Data

• Hazardous Substances Data: 30069-31-9(Hazardous Substances Data)

Upstream product

• 221876-21-7 N-(4-methyl-3-nitrophenyl)-3-(trifluoromethyl)benzamide 
• 2251-65-2 3-(Trifluoromethyl)benzoyl chloride 
• 119-32-4 4-Methyl-3-nitroanilin 
• 89-58-7 mononitro-p-xylene 
• 454-92-2 3-(trifluoromethyl)benzoic acid 

Downstream Products

• 221876-21-7 N-(4-methyl-3-nitrophenyl)-3-(trifluoromethyl)benzamide 
• 879507-30-9 3-trifluoromethyl-N-(3-guanidino-4-methyl-phenyl)-benzamide nitrate 
• 839708-51-9 N-{3-[(2-chloro-4-methylaminopyrimidin-5-ylmethyl)amino]-4-methylphenyl}-3-trifluoromethylbenzamide 
• 839708-56-4 4-amino-2-methylsulfanylpyrimidine-5-carboxylic acid [2-methyl-5-(3-trifluoromethylbenzoylamino)phenyl]amide 
• 940311-36-4 N-{3-[1-(4-bromophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-4-methyl-phenyl}-3-trifluoromethyl-benzamide 
• 946422-13-5 N-[4-methyl-3-(6-methylsulfanyl-[4,5']bipyrimidinyl-4'-ylamino)-phenyl]-3-trifluoromethyl-benzamide 
• 1135219-23-6 ALW-II-49-7 
• 1186206-77-8 6-amino-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)nicotinamide 
• 1186206-78-9 N-(3-(2-(1H-indol-3-yl)-2-oxoacetamido)-4-methylphenyl)-3-(trifluoromethyl)benzamide 
• 1186206-82-5 ALW-II-49-5 
• 1186206-76-7 2-amino-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)isonicotinamide 
• 958840-14-7 3-(9H-purin-6-ylamino)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide 
• 1160702-98-6 4-(4-trifluoromethoxyphenylamino)thieno[2,3-d]pyrimidine-6-carboxylic acid [2-methyl-5-(3-trifluoromethylbenzoylamino)phenyl]amide 
• 1258507-29-7 C₃₆H₃₅F₃N₈O₄ 

Relevant articles and documents

Evaluation of carbon-11 labeled 5-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)nicotinamide as PET tracer for imaging of CSF-1R expression in the brain

Pharmacological targeting of tumor associated macrophages and microglia in the tumor microenvironment is a novel therapeutic strategy in the treatment of glioblastoma multiforme. As such, the colony stimulating factor-1 receptor (CSF-1R) has been identified as a druggable target. However, no validated companion diagnostic marker for these therapies exists to date. Towards development of a CSF-1R PET tracer, a set of six compounds based on recently reported CSF-1R inhibitor 5-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)nicotinamide (Compound 5) was designed, synthesized and evaluated in vitro for potency and selectivity. The highest affinity for CSF-1R was found for compound 5 (IC50: 2.7 nM). Subsequent radiosynthesis of [11C]5 was achieved in 2.0 ± 0.2% yield (decay corrected to start of synthesis) by carbon-11 carbon monoxide aminocarbonylation in 40 min after end of bombardment. In vitro autoradiography with [11C]5 on rat brain sections demonstrated high specific binding, but also strong off-target binding. Ex vivo, only intact tracer was observed in blood plasma at 90 min post injection in healthy rats. PET scanning results demonstrated negligible brain uptake under baseline conditions and this brain uptake did not increase by blocking of efflux transporters using Tariquidar. To conclude, [11C]5 was successfully synthesized and evaluated in healthy rats. However, the inability of [11C]5 to cross the blood-brain-barrier excludes its use for imaging of CSF-1R expression in the brain.

DUAL SRC/P38 KINASE INHIBITOR COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS

Dual Src/p38 kinase inhibitor compounds and compositions comprising the same are disclosed. Methods of using the compounds in the treatment of hyperproliferative disease such as cancer are also disclosed.

Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors

By combining the scaffolds of UI-125 and Sorafenib, a series of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine moiety were designed and synthesized as novel DFG-out B-RafV600E inhibitors. Among them, 20c-e, 20g and 21h displayed potent antiproliferative activities against melanoma A375 (B-RafV600E) cell lines with IC50 values of 3.190, 2.276, 1.856, 1.632 μM and 1.839 μM, respectively, comparable with the positive control Vemurafenib (IC50 Combining double low line 3.32 μM). Selected compounds were tested for the ERK inhibition in human melanoma A375 (B-RafV600E) and SK-MEL-2 (B-RafWT) cell lines by Western blot. The results revealed that our compounds inhibited the proliferation of melanoma A375 cells (B-RafV600E) through ERK pathway, without paradoxical activation of ERK in melanoma SK-MEL-2 cells (B-RafWT). Eventually, 20g and 21h were selected to confirm their inhibitory effects on tumor growth in A375 xenograft models in mice. Compound 20g exhibited equivalent antitumor efficacy in vivo (T/C Combining double low line 44.37%), compared to Sorafenib (T/C Combining double low line 37.35%), by 23-day repetitive administration of a single dose of 50 mg/kg without significant body weight loss.